AN2 Therapeutics (ANTX) vs Korro Bio (KRRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Korro Bio (KRRO) over the past year, gaining 184.0% versus a loss of 79.9%. AN2 Therapeutics is the larger company by market cap ($127.5 million vs $125.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | KRRO |
|---|---|---|
| Share price | $3.38 | $8.49 |
| Market cap | $127.55M | $125.02M |
| 1-day change | -6.11% | -8.81% |
| YTD return | +196.49% | +5.99% |
| 1-year return | +184.03% | -79.86% |
| 5-year return | — | -97.48% |
| EPS (TTM) | $-1.05 | $-9.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.39M |
| Revenue growth (YoY) | — | +181.46% |
| Net income (latest FY) | $-35.17M | $-117.26M |
| Operating margin | — | -1906.37% |
| Net margin | — | -1834.48% |
| 52-week high | $7.19 | $48.70 |
| 52-week low | $1.00 | $5.20 |
| Distance from 52-week high | -52.99% | -82.57% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +166.27% | +137.93% |
| Average volume | 251.53K | 151.92K |
| Shares outstanding | 37.74M | 14.73M |
| Employees | 21 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed KRRO by 263.9 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
ANTX vs KRRO FAQ
Which is bigger, AN2 Therapeutics or Korro Bio?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $127.55M compared with $125.02M for Korro Bio (KRRO).
Which stock has performed better over the past year, ANTX or KRRO?
ANTX returned +184.03% over the past 12 months, compared with -79.86% for KRRO (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Korro Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.